Clinical and cognitive risk factors for psychotic symptoms in 22q11.2 deletion syndrome: a transversal and longitudinal approach by Maude Schneider et al.
ORIGINAL CONTRIBUTION
Clinical and cognitive risk factors for psychotic
symptoms in 22q11.2 deletion syndrome: a
transversal and longitudinal approach
Maude Schneider • Marie Schaer • A. Kadir Mutlu •
Sarah Menghetti • Bronwyn Glaser •
Martin Debbane´ • Stephan Eliez
Received: 18 December 2012 / Accepted: 18 August 2013 / Published online: 3 September 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract 22q11.2 deletion syndrome (22q11DS) is
associated with increased risk for schizophrenia. Better
identifying risk factors for the emergence of psychotic
symptoms in this population is needed to improve clinical
assessment and early interventions. Schizophrenia spec-
trum disorders, hallucinations and delusions were charac-
terized in an original sample of 104 individuals with
22q11DS. Further analysis of positive and negative
symptoms was performed in a subsample of 59 individuals.
Finally, longitudinal data available in 56 patients were used
to explore the developmental trajectories of psychotic
symptoms as well as the associations between psychotic
symptoms and cognitive functioning. Schizophrenia spec-
trum disorders and psychotic symptoms were frequent in
adolescent and adults with 22q11DS. The severity of hal-
lucinations and non-persecutory delusional ideas
discriminated patients at ultra-high risk for conversion to
psychosis. Whereas approximately one-third of patients
experienced an emergence of psychotic symptoms during a
4-year interval, 20 % displayed transient symptoms. Indi-
viduals with psychotic symptoms were characterized by a
lower cognitive functioning in the context of the 22q11DS.
The present study adds important data on the characteris-
tics and developmental trajectory of psychotic symptoms in
this population. This information may ultimately help cli-
nicians dealing with these patients to reduce the duration of
untreated psychosis and improve outcome.
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Introduction
22q11.2 deletion syndrome (22q11DS) is associated with a
high risk of developing schizophrenia [1], a psychiatric
condition that leads to a high degree of disability, family
burden and cost for society [2]. Identifying reliable risk
factors for the onset of psychotic symptoms represents an
important objective for research on 22q11DS. Furthermore,
combining investigations into neurobiological, cognitive
and clinical aspects of the syndrome will strengthen our
ability to accurately predict risk for schizophrenia. In the
present paper, we focus exclusively on clinical and cog-
nitive risk factors, as they translate more easily to clinical
implications of the syndrome.
Previous studies suggest that attenuated or brief inter-
mittent psychotic manifestations, such as isolated halluci-
nations and subthreshold delusional ideas, are frequent in
children and adolescents with 22q11DS and represent one
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of the strongest predictors for the onset of a full-blown
psychotic disorder [3, 4]. However, no study to date has
investigated in detail the phenomenology and develop-
mental trajectory of psychotic symptoms in this population.
Furthermore, although negative symptoms are frequent and
often severe in 22q11DS youth [5, 6], their role in the
pathogenesis of schizophrenia has been less clearly estab-
lished. In our opinion, a clear description of these mani-
festations may improve our ability to predict the onset of
schizophrenia and reduce the duration of untreated psy-
chosis in these at-risk patients.
When aiming at accurately predicting the onset of psy-
chotic symptoms, a careful assessment of the cognitive
status in these patients may also add valuable information.
Indeed, research in schizophrenia shows that deficits in
some cognitive areas are already present from childhood
and remain relatively independent of positive symptom-
atology over time [e.g. 7, 8]. In particular, low IQ as well
as deficits in executive functioning, working memory and
attention has been described as early trait cognitive
markers for schizophrenia [9–11]. On the other hand, some
cognitive abilities may deteriorate just before or during the
onset of full-blown psychosis, thereby representing proxi-
mal state markers for schizophrenia. According to From-
mann [12], working memory, and verbal and visual
memory deficits worsen just before the onset of psychosis,
whereas executive dysfunction may reflect a more stable
aspect of the disease. In 22q11DS, few longitudinal studies
have examined cognitive risk factors for psychotic symp-
toms. They observed that a decline in verbal IQ, low verbal
abilities and executive functioning during childhood pre-
dicted the severity of psychotic symptoms later in life [13,
14].
The present study combines cross-sectional and longi-
tudinal data acquired within the 22q11DS Swiss longitu-
dinal study since 2002. Firstly, cross-sectional data
collected in a large cohort of patients were used to char-
acterize positive psychotic symptoms and schizophrenia
spectrum disorders in this population. As already described
in previous studies [e.g. 1, 3, 15], we expected to observe a
high prevalence of positive psychotic symptoms and
schizophrenia spectrum disorders in adolescents and adults
with 22q11DS. Secondly, we examined which dimension
of positive and negative symptoms best distinguish indi-
viduals at different stages of psychosis (non-prodromal, at-
risk mental state and psychotic state). Based on previous
publications [3, 16], we hypothesized that the severity of
hallucinations would best discriminate between these
stages. We also explored if the severity of negative
symptoms was increased in patients in an at-risk mental
state. Thirdly, using longitudinal data available for a sub-
sample of patients, we characterized the different devel-
opmental trajectories of positive psychotic symptoms over
time. Indeed, our clinical experience suggests that psy-
chotic symptoms do not recede spontaneously in most
22q11DS patients, but a small percentage of them may
experience transient psychotic symptoms. To our knowl-
edge, this has never been examined in previous studies and
warrants investigation due to the direct implications for
clinical practice. Finally, using the longitudinal dataset, we
examined the developmental trajectory of cognitive func-
tioning in participants with and without psychotic symp-
toms to identify putative trait and state markers for the
presence of psychotic symptoms. Based on previous lon-
gitudinal studies in 22q11DS and schizophrenia [13, 14],
we expected that the presence of psychotic symptoms
would be associated with low general intellectual func-
tioning (trait marker) and a decrease in memory function-
ing and verbal reasoning abilities (state markers).
Method
Participants
This cohort has been the subject of previous publications
and the global research strategy has already been published
elsewhere [e.g. 17]. Briefly, all participants were recruited
through advertisements in patient association newsletters
and through word of mouth. Written informed consent was
obtained for all participants and their parents under the
protocols approved by the Institutional Review Board of
the Department of Psychiatry of the University of Geneva
Medical School. The presence of a 22q11.2 microdeletion
was confirmed using quantitative fluorescent polymerase
chain reaction (QF-PCR).
The results from the present study were obtained by
analysing cross-sectional data in an original sample of 104
individuals with 22q11DS. They were further completed by
additional analyses performed on a cross-sectional sub-
sample of 59 individuals and a longitudinal subsample of
56 individuals (see Table 1).
The original sample of 104 participants with 22q11DS
of age 6–44 years [mage = 14.83, SD = 7.53; 57 (55 %)
females] was used to characterize the prevalence of hal-
lucinations and delusional ideas. The sample was subdi-
vided into three age groups to compare the prevalence of
these manifestations across their lifespan: children aged
6–11 years (N = 45); adolescents aged 12–17 years
(N = 39); and adults above 18 years (N = 20). Seventeen
(16.3 %) participants were receiving psychotropic medi-
cation at the time of testing: six were on methylphenidate,
six on antipsychotics, five on antidepressants, three on
antiepileptic drugs and two on anxiolytic medication.
As data collected in this large sample remained rela-
tively general, we performed more detailed analyses in a
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cross-sectional subsample of participants using the Struc-
tured Interview for Prodromal Syndromes (SIPS; see
‘‘Materials’’). The SIPS was introduced later into the
Geneva longitudinal study research protocol and is not
appropriate for use with young children. SIPS data were
available for a subsample of 59 participants (mage = 16.93,
SD = 5.67; 33 (56 %) females]. Patients assessed with the
SIPS were significantly older compared with patients who
were not assessed with the SIPS (t = -3.423, p = 0.001),
but did not differ regarding gender distribution
(v2 = 0.070, df = 1, p = 0.792), mean full-scale IQ
(t = -0.515, p = 0.608) and mean BPRS positive symp-
tom score (t = -1.460, p = 0.147). The prevalence of
patients receiving psychotropic medication did not signif-
icantly differ between the two groups (v2 = 0.527, df = 1,
p = 0.468). The difference in age was due to the fact that
the SIPS was not administered to younger children.
Subsequent to cross-sectional analyses, we analysed the
evolution of psychotic symptoms in our cohort using the
longitudinal data collected to date with the Brief Psychi-
atric Rating Scale (BPRS; see ‘‘Materials’’). These analy-
ses enabled examining the developmental trajectories of
positive psychotic symptoms as well as the association
between positive psychotic symptoms and cognitive func-
tioning. Longitudinal assessments were available for 63
participants, of whom we excluded 7 aged below 12 years
at T2 evaluation to limit the probability of false negatives
(i.e. participants with no apparent psychotic symptoms who
may still develop symptoms later in life). The final longi-
tudinal subsample was therefore composed of 56 patients
[mage at T1 = 16.60, SD = 6.73; 33 (59 %) females], with
a mean interval of 3.86 years between the two visits
(SD = 0.69 year, range 2.57–6.00 years). Patients for
whom longitudinal data were not available did not differ
from patients assessed longitudinally regarding age (t =
-1.276, p = 0.205), gender distribution (v2 = 0.657,
df = 1, p = 0.417), full-scale IQ (t = -0.924, p = 0.358)
and mean BPRS positive symptom score (t = -0.921,
p = 0.359). The prevalence of patients receiving psycho-
tropic medication did not significantly differ between the
two groups (v2 = 2.398, df = 1, p = 0.121).
Materials
Clinical evaluation
All participants and their parents were interviewed sepa-
rately by a trained psychiatrist (SE). Parents of participants
below the age of 18 years were interviewed using the
computerized Diagnostic Interview for Children and Ado-
lescents-Revised [DICA-R; 18] to identify the presence of
DSM-IV psychiatric disorders in their children. All diag-
noses were confirmed during a clinical evaluation of the
child. Adult participants and their parents were interviewed
using the Structured Clinical Interview for DSM-IV Axis I
disorders [SCID-I; 19]. The psychotic disorders supple-
ment of the Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children Present and Lifetime
Version [K-SADS-PL; 20] was also used with all partici-
pants and their parents to complete the clinical evaluation.
The K-SADS-PL rates the presence of hallucinations and
delusions using a three-point severity scale (1 = absent;
2 = subthreshold; 3 = definite).
During the participants’ clinical evaluation, two sup-
plementary instruments were used. The Structured Inter-
view for Prodromal Syndromes [SIPS; 21, 22] was
administered to assess positive, negative, disorganization
and general prodromal symptoms. Before administering the
SIPS, the interviewer (SE) clinically assessed if the par-
ticipant had a sufficient level of abstract thinking to
understand and answer to the SIPS items. During the
interview, each symptom was rated on a 7-point severity
scale (0 = absent to 6 = severe). The presence of a psy-
chotic syndrome or an at-risk mental state was based on the
Criteria for Prodromal Syndromes (COPS 3.0). The Brief
Psychiatric Rating Scale [BPRS; 23] was administered to
assess positive psychotic symptoms. According to Nich-
olson et al. [24], four BPRS symptoms are used as proxy
measures for positive psychotic symptoms in the vast
majority of studies: hallucinatory behaviour, suspicious-
ness, unusual thought content and conceptual disorgani-
zation. In the present study, we decided to exclude the
conceptual disorganization item, as it might be influenced
Table 1 Sample description

















56 (58 % of the
original sample)
T1: m = 16.60
(SD = 6.73)
23/33 BPRS
T2: m = 20.46
(SD = 6.84)
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by the cognitive difficulties experienced by individuals
with 22q11DS. The presence of positive symptoms was
therefore assessed by the following BPRS items: halluci-
natory behaviour, suspiciousness and unusual thought
content. Presence of positive symptoms was determined by
a score C3 on at least one of these items.
Cognitive functioning
Cognitive functioning was assessed in all participants at T1
and T2 evaluations. Participants younger than 17 years
completed the Wechsler Intelligence Scale for Children III
[WISC-III; 25] and the Children’s Memory Scale [CMS;
26]. Participants older than 17 completed the Wechsler
Adult Intelligence Scale III [WAIS-III; 27] and the
Wechsler Memory Scale III [WMS-III; 28]. WISC-III/
WAIS-III index scores (full-scale IQ, verbal IQ, perfor-
mance IQ, verbal comprehension index, perceptual orga-
nization index, and processing speed index) were used as
global measures of verbal and visuo-spatial reasoning as
well as processing speed. CMS/WMS-III indices (auditory
immediate, auditory delayed, visual immediate, visual
delayed and auditory recognition delayed) were used as
measures of memory functioning.
Statistical analyses
The first analyses were based on cross-sectional data and
performed using SPSS version 19. We first compared the
prevalence of schizophrenia spectrum disorders (based on
the DICA, SCID-I and K-SADS-PL), definite hallucinations
and delusions, and subthreshold hallucinations and delu-
sions (based on the K-SADS-PL) across age groups using
Chi-square tests. Hallucinations were then characterized
according to their modalities of expression (auditory, visual
or combined forms); delusions were characterized accord-
ing to their thematic forms (referential, persecutory or
combined forms).
Patients with SIPS data available (N = 59) were divided
into three groups based on the COPS 3.0. criteria: presence
of a psychotic syndrome, presence of an at-risk mental
state and non-prodromal individuals. The severity of the
SIPS positive and negative symptoms was compared
between the three groups using Kruskal–Wallis tests with
pairwise comparisons of category (accounting for multiple
comparisons). Non-parametric analyses were used because
of the abnormal distribution of the data and sample size
differences between the groups.
The second analyses were based on longitudinal data
available for a subsample of 56 patients. We first examined
the prevalence of different clinical trajectories of positive
psychotic symptoms over time: absence of symptoms (i.e.
score \3 on the three BPRS items assessing positive
symptoms at T1 and T2 evaluation), transient symptoms
(i.e. score C3 on at least one positive BPRS item at T1 and
score \3 on positive BPRS items at T2), emerging symp-
toms (i.e. score\3 on positive BPRS items at T1 and score
C3 on at least one positive BPRS item at T2) and enduring
symptoms (i.e. score C3 on at least one positive BPRS item
at T1 and T2).
We then examined the developmental trajectories of
cognitive functioning in patients with and without positive
psychotic symptoms at T2. A score C3 on at least one
positive BPRS item was used to determine the presence of
positive psychotic symptoms. These analyses were per-
formed using mixed model regression analyses, allowing to
model the within-subject factor as a nested variable [29].
Such mixed model analyses allow increased statistical
Table 2 Frequency of schizophrenia spectrum disorders, definite psychotic symptoms, and subthreshold psychotic symptoms across age groups
Children
6–11 y.o. (N = 45)
Adolescents
12–17 y.o. (N = 39)
Adults




Any schizophrenia spectrum disorder 0 (0 %) 3 (8 %) 7 (35 %) 10 (10 %) \0.001
Schizophrenia 0 (0 %) 1 (3 %) 2 (10 %) 3 (3 %)
Schizoaffective disorders 0 (0 %) 0 (0 %) 3 (15 %) 3 (3 %)
Other psychotic disordersa 0 (0 %) 2 (5 %) 2 (10 %) 4 (4 %)
Any definite psychotic symptom 0 (0 %) 9 (23 %) 7 (35 %) 16 (15 %) \0.001
Definite hallucinations 0 (0 %) 9 (23 %) 6 (30 %) 15 (14 %)
Definite delusions 0 (0 %) 4 (10 %) 5 (25 %) 9 (9 %)
Any subthreshold psychotic symptom 7 (16 %) 12 (31 %) 8 (40 %) 27 (26 %) 0.080
Subthreshold hallucinations 4 (9 %) 6 (15 %) 4 (20 %) 14 (13 %)
Subthreshold delusions 4 (9 %) 7 (18 %) 7 (35 %) 18 (17 %)
a Schizophreniform disorder, delusional disorder, brief psychotic disorder, and psychotic disorder NOS
428 Eur Child Adolesc Psychiatry (2014) 23:425–436
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power in longitudinal dataset such as ours, with variable
time between visits and a large age range at T1 evaluation.
Different random intercept models (constant, linear, qua-
dratic and cubic) were proposed, using the nlmefit function
in MATLAB R2011b (MathWorks). We used a Bayesian
information criterion (BIC)-based model selection method,
as the BIC-based methods are one of the most powerful
model selection methods for the mixed models [30]. Then,
a likelihood ratio test was used to quantify significant
between-group differences in the cognitive trajectories
over time. At the end of the analysis, two types of differ-
ences can be observed between the groups: shape differ-
ences (the trajectories of cognitive functioning in the two
groups have a different shape) and intercept differences
(the trajectories in the two groups have the same shape (i.e.
they are parallel), but have different intercept values).
Results
Cross-sectional analyses
Prevalence of schizophrenia spectrum disorders
and positive psychotic symptoms
The prevalence of schizophrenia spectrum disorders and
positive psychotic symptoms was examined in the original
sample of 104 individuals. Schizophrenia spectrum
Fig. 1 Frequency and characterization of positive psychotic symp-
toms by age group in the original sample (N = 104, cross-sectional
design). a Percentage and modality of expression of subthreshold and
definite hallucinations by age group; b percentage and main thematic
of subthreshold and definite delusions by age group
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disorders were diagnosed in 10 % of individuals (see
Table 2). Their prevalence was significantly different
between age groups (v2 = 19.782, df = 2, p \ 0.001), with
a higher rate among adults. The youngest patient diagnosed
with a schizophrenia spectrum disorder was aged 15.
The prevalence of individuals experiencing definite hal-
lucinations and/or delusions in the total sample was 20 %
(see Table 1). Again, their prevalence differed between age
groups (v2 = 15.866, df = 2, p \ 0.001), with higher rates
in adults. The frequency of individuals experiencing sub-
threshold hallucinations and/or delusions in the total sample
was 26 %. The prevalence was not significantly different in
the three age groups (v2 = 5.055, df = 2, p = 0.080).
Subthreshold hallucinations were observed in children
as young as 6 years old, whereas definite hallucinations
were seen from adolescence only (the youngest participant
with definite hallucinations was aged 12). Auditory hallu-
cinations were the most frequent in all age groups, fol-
lowed by visual hallucinations (see Fig. 1a). When other
types of hallucinations (e.g. olfactory) were present, it was
always in combination with auditory hallucinations.
Combined forms of hallucinations (i.e. hallucinations in
two or more modalities) were rare in patients with sub-
threshold hallucinations (1 case), but frequent in patients
with definite hallucinations (30 % of cases).
As for hallucinations, subthreshold delusions were
observed in few children aged 10 years or higher, whereas
definite delusions were rarer and seen from adolescence
only (the youngest participant with definite delusions was
aged 15) (see Fig. 1b). Ideas of reference (i.e. subthreshold
delusions with a referential theme) and subthreshold per-
secutory delusions were the most frequent forms of sub-
threshold delusions at all ages (6.73 and 3.85 % of the total
sample, respectively). Delusions of reference (i.e. definite
delusions with a referential theme) and definite persecutory
delusions also were the most frequent forms of definite
delusions at all ages (each affecting 1.92 % of the total
sample). When other forms of subthreshold or definite
delusions were present (e.g. grandiose theme), it was always
in combination with a referential or a persecutory theme.
Psychotic symptoms across different stages of psychosis
SIPS data were available in a subsample of 59 participants
from the original cross-sectional sample of 104 individuals.
According to the COPS 3.0. criteria, six participants
(m = 21.55, SD = 6.99; 1 female) had a current psychotic
syndrome and seven were in an at-risk mental state
(m = 16.41, SD = 4.31; 2 females). The remaining 46
participants (m = 16.41, SD = 5.52; 30 females) com-
prised the non-prodromal group. Kruskal–Wallis omnibus
tests on the SIPS positive and negative symptom scores
were all significant (p \ 0.05). Pairwise comparisons of
category (with adjusted p values) revealed that individuals
in an at-risk mental state had significantly higher scores on
items P1 (delusional ideas) (rank difference = -17.590,
p = 0.021), P3 (grandiosity) (rank difference = -8.286,
p = 0.018) and P4 (hallucinations) (rank difference =
-18.194, p = 0.016) compared to the non-prodromal
group (see Fig. 2). They did not differ on items P2 (sus-
piciousness), P5 (disorganized communication) and on the
six items assessing negative symptoms (all p [ 0.05). The
comparison between the at-risk and the psychotic syn-
drome groups revealed a significant difference in item
P5 (disorganized communication) (rank difference =
-21.500, p = 0.028) and item N3 (expression of emotions)
(rank difference = -24.048, p = 0.029). Finally, individ-
uals from the psychotic syndrome group had significantly
higher scores on all positive and negative items than non-
prodromal individuals (all p \ 0.05).
Longitudinal analyses
Developmental trajectory of positive psychotic symptoms
We characterized the different trajectories of positive psy-
chotic symptoms using longitudinal data acquired on a sub-
sample of 56 patients aged at least 12 years old at the second
evaluation. A proportion of 30.4 % (N = 17) of patients
showed no positive psychotic symptoms at either time point,
23.2 % (N = 13) displayed transient symptoms, 19.6 %
(N = 11) showed emerging positive psychotic symptoms and
26.8 % (N = 15) displayed enduring positive psychotic
symptoms (see Fig 3a). All the participants receiving anti-
psychotic medication either at T1 (N = 3) or T2 (N = 7)
evaluations were part of the group of patients with enduring
positive psychotic symptoms. For visualization purpose, the
trajectories of the mean BPRS positive symptom score (mean
severity score of BPRS hallucinatory behaviour, suspicious-
ness, and unusual thought content items) in the four groups are
displayed in Fig. 3b. Changes in the mean BPRS positive
symptom score between the two visits are also shown as a
function of age (see Fig. 3c). A binomial test revealed that
patients with emerging symptoms were significantly more
often under the age of 18 years (9 patients under the age of 18
vs. 2 patients above the age of 18: one-tail p = 0.033). This
was not the case for patients with no positive psychotic
symptoms (one-tail p = 0.166), transient symptoms (one-tail
p = 0.500), or enduring symptoms (one-tail p = 0.304).
Cognitive trajectories in patients with and without positive
psychotic symptoms
Finally, we compared the cognitive trajectories in indi-
viduals with (N = 26) and without (N = 30) positive
psychotic symptoms at T2 (see Table 3). Contrary to our
430 Eur Child Adolesc Psychiatry (2014) 23:425–436
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hypothesis, we observed no significant difference in the
shape of the trajectories between the two groups. However,
we observed a significant intercept difference for several
cognitive domains. In most cases, the trajectories were
linearly decreasing over time, with a significant intercept
difference between the two groups in favour of individuals
without positive psychotic symptoms (see Fig. 4). This
included full-scale IQ (p = 0.034), the processing speed
index (p = 0.027), and the delayed recognition memory
index (p = 0.046). Other domains were stable with age,
with a significant interecept difference in favour of patients
without psychotic symptoms. This was the case for per-
formance IQ (p = 0.011) and the perceptual organization
index (p = 0.033).
The trajectories in the remaining cognitive domains did
not significantly differ between the two groups. Some
domains were stable with age (auditory immediate memory
index, auditory delayed memory index, visual immediate
memory index, and visual delayed memory index),
whereas other declined with age (verbal IQ and verbal
comprehension index).
Discussion
In the present article, we characterized positive psychotic
symptoms and schizophrenia spectrum disorders in a large
cross-sectional sample of patients with 22q11DS. In
Fig. 2 Mean severity of SIPS positive (a) and negative (b) symptoms
according to clinical status. The mean score on each SIPS item for the
three groups is provided at each corner of the graph. Significant
differences are based on Kruskal–Wallis tests with pairwise compar-
isons of category
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accordance with our first hypothesis, we observed a high
prevalence of positive psychotic symptoms and schizo-
phrenia spectrum disorders in adolescents and adults with
22q11DS. In accordance with our second hypothesis and
based on analyses performed using the SIPS, we observed
that the severity of hallucinations distinguished between
non-prodromal patients and at-risk patients. Our results
also suggest that the severity of grandiosity and non-
persecutory delusional ideas is also discriminant. However,
the severity of negative symptoms did not differ between
these two groups of patients. Using longitudinal data
available in a subsample of 56 patients, we observed that
27 % of patients experienced positive psychotic symptoms
of increasing severity over time and that these patients
were aged below 18 years in the majority of cases. On the
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Fig. 3 Longitudinal trajectories of the BPRS positive symptom
score. a Percentage of the sample included in the four groups of
patients: no positive psychotic symptoms, transient symptoms,
emerging symptoms, and enduring symptoms. b Graphical represen-
tation of the BPRS positive symptom score at T1 and T2 evaluations
in the four groups of patients. T1 and T2 scores of the same
participant are connected with a dashed line. c Graphical represen-
tation of the BPRS positive symptom score change between the two
visits. Significantly more patients with emerging symptoms were
under the age of 18 years (9 patients under the age of 18 vs. 2 patients
above the age of 18)
Table 3 Mean (SD) cognitive scores at T1 and T2 in patients with and without positive psychotic symptoms at follow-up evaluation
Cognitive measures Without positive psychotic symptoms at follow-up With positive psychotic symptoms at follow-up
T1 T2 T1 T2
WISC-III/WAIS-III indices
Full-Scale IQ 73.60 (11.54) 71.80 (11.39) 68.54 (11.59) 64.35 (9.98)
Verbal IQ 78.00 (14.28) 74.70 (14.06) 74.88 (14.10) 68.96 (13.07)
Performance IQ 73.73 (10.54) 72.97 (10.29) 67.85 (12.16) 65.12 (10.94)
Verbal comprehension index 82.10 (14.01) 78.80 (14.70) 77.77 (14.60) 72.85 (12.25)
Perceptual organization index 74.50 (10.66) 73.10 (10.56) 69.08 (11.82) 67.08 (11.11)
Processing Speed Index 82.43 (14.32) 80.30 (16.78) 75.12 (17.99) 70.31 (16.55)
CMS/WMS-III indices
Visual immediate 81.13 (13.78) 79.20 (13.31) 74.36 (15.42) 74.04 (19.19)
Visual delayed 82.40 (16.84) 82.57 (11.26) 77.28 (15.51) 74.42 (18.26)
Auditory immediate 94.27 (15.09) 87.60 (14.94) 83.24 (17.52) 82.00 (17.09)
Auditory delayed 94.47 (16.08) 88.83 (15.11) 83.52 (19.37) 84.04 (17.74)
Auditory recognition delayed 97.17 (11.63) 89.80 (12.11) 89.40 (16.88) 85.57 (19.00)
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transient symptomatology. Finally, we identified several
cognitive scores, such as full-scale IQ, processing speed,
and verbal memory, as putative trait markers for the
presence of psychotic symptoms. Contrary to our hypoth-
esis, no state markers for the presence of psychotic
symptoms were identified.
Characterization of schizophrenia spectrum disorders
and positive psychotic symptoms in 22q11DS
In the present sample, we observed a high prevalence of
schizophrenia spectrum disorders in adults with 22q11DS,
similar to what was typically observed in other research
groups [e.g. 1]. Furthermore, we observed that the rate of
schizophrenia spectrum disorders was also increased in the
adolescent group (8 %), suggesting that early-onset psy-
chosis in frequent in 22q11DS and may represent a clinical
characteristic of the syndrome [31, 32]. Indeed, the onset
occurred before the age of 18 years in 30 % of individuals
with a schizophrenia spectrum disorder. Although the exact
prevalence of early-onset schizophrenia (i.e. onset before
18 years) in schizophrenic patients without 22q11DS
remains unknown, the 30 % prevalence observed in the
present study is much higher than the estimated rate of
early-onset schizophrenia [e.g. 33]. For this reason, child
and adolescent psychiatrists unfamiliar with 22q11DS may
misdiagnose psychotic symptoms in these adolescents.
Because the duration of untreated psychosis is known to
affect outcome [34], it thus becomes increasingly important
to heighten practitioners’ awareness about the specificities
of schizophrenia spectrum disorders in the context of
22q11DS.
When psychotic symptoms were examined in the same
sample of patients, it appeared that a substantial proportion
of them reported psychotic manifestations in the absence of
a full-blown psychotic disorder and even at a very young
age [see also 3, 31]. Taken together, subthreshold and
definite positive psychotic symptoms were experienced by
more than 50 % of adolescents and 75 % of adults with
22q11DS. When subthreshold and definite positive psy-
chotic symptoms were examined separately, this revealed
that subthreshold manifestations already emerged in few
children, whereas definite symptoms were present from
adolescence only. In general, hallucinations tended to
emerge earlier than delusional ideas (the youngest patient
experiencing definite hallucinations was aged 12 years,
whereas the youngest patient experiencing definite delu-
sions was aged 15). This goes in favour of Garety’s model
of positive symptoms [35], which argues that delusional
ideas account for the presence of anomalous experiences
and therefore follow the onset of hallucinations in the
majority of cases. The description of the phenomenology of
positive psychotic symptoms in this population is generally
consistent with the previous description of Vorstman et al.
[32]. We observed that hallucinations were more frequently
auditory than visual and that delusions were predominantly
referential. Our results also suggest that combined forms of
hallucinations and delusions were almost exclusively
present in patients with definite psychotic symptoms and
rarely observed in patients with subthreshold manifesta-
tions. Altogether, these data suggest that psychosis in
22q11DS should not be considered as an all-or-nothing
phenomenon, but rather as a continuum of psychotic
experiences of increasing severity. This also underlines the
importance of carefully assessing psychotic manifestations
in 22q11DS individuals, even in the paediatric population.
However, our clinical experience suggests that these
patients are often reluctant to share their experiences for
fear of being judged negatively, particularly with their
families. For this reason, clinicians should always spend
time alone with the patient and investigate the presence of
symptoms using detailed and oriented questions. In par-
ticular, a careful assessment of auditory hallucinations and
ideas/delusions of reference should be performed.
Evolution of the severity of psychotic symptoms
over time
The comparison of positive and negative symptoms in
participants at different stages of psychosis revealed that
the severity of hallucinations, non-persecutory delusional
ideas, and grandiosity discriminate between at-risk patients
and non-prodromal individuals. Disorganized communi-
cation distinguished at-risk patients and individuals with a
psychotic syndrome. These results suggest that hallucina-
tions, delusional ideas such as mind reading, ideas of ref-
erence, or magical thinking are among the first positive
symptoms that are likely to appear in 22q11DS youth. On
the contrary, it suggests that more disorganized aspects of















without positive psychotic symptoms
with positive psychotic symptoms
Fig. 4 Developmental trajectory of full-scale IQ in participants with
and without psychotic symptoms. The trajectories in the two groups
have a significantly different intercept value
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the behaviour are more likely to appear during the transi-
tion to a full-blown psychotic state. Based on our clinical
experience with this population, we recommend instituting
an antipsychotic medication to avoid an evolution of
symptomatology towards disorganization when psychotic
symptoms are present more than once a month or are
described as intrusive. By contrast, we observed that the
severity of negative symptoms did not discriminate at-risk
patients from non-prodromal individuals. There are at least
two possible interpretations for this result. On one hand,
negative-like symptoms may be a characteristic of the
22q11DS clinical profile and may not be specifically rela-
ted to the development of psychosis in this population. For
example, these manifestations could be related to cognitive
deficits. On the other hand, negative symptoms may predict
the development of psychosis, while preceding the onset of
positive symptoms. This interpretation is commensurate
with Dominguez et al. [36], who suggest that negative
symptoms appear several years before the onset of positive
symptoms and predict their occurrence. Furthermore,
negative symptoms have been shown to predict transition
to schizophrenia [37, 38]. Future longitudinal studies in
22q11DS examining the predictive value of negative
symptoms in the conversion to schizophrenia will help
clarify these alternative interpretations.
In accordance with our third hypothesis, we observed
that positive psychotic symptoms had different trajectories
of evolution over time. Indeed, approximately one-third of
the sample experienced emerging symptoms between T1
and T2 evaluations. These patients were below the age of
18 years in 82 % of cases, suggesting that the period of
maximum risk for conversion to psychosis is relatively
limited in time and occurs during adolescence in the great
majority of cases. This should motivate clinicians to per-
form clinical evaluations at more regular intervals during
this period and be particularly vigilant about symptom
exacerbation. On the contrary, 20 % of the sample experi-
enced transient psychotic symptoms during the 4-year
interval, an interesting finding that has never been reported
thus far in this population. As no patient from this subgroup
received antipsychotic medication at T1 or T2 evaluations,
one cannot assume that symptoms decreased due to a
pharmacological intervention. It is either possible that the
course of positive psychotic symptoms is naturally transient
in some individuals with 22q11DS, or that symptoms were
reduced during this period due to an active management of
known risk factors for the development of psychotic
symptoms (e.g. anxiety management, psychoeducation
focused on cannabis use, etc.). Future studies on 22q11DS
should further investigate the characteristics of this sub-
group of patients, which could give important insights into
adequate intervention strategies for the management of
psychotic symptoms in this population.
Associations between positive psychotic symptoms
and cognitive functioning
We observed that most cognitive domains were linearly
decreasing over time both in patients with and without
positive psychotic symptoms. In accordance with other
studies [e.g. 39], this suggests that 22q11DS is associated
with a general cognitive decline over time, which partic-
ularly affects verbal reasoning abilities and processing
speed. However, perceptual organization, verbal and visual
memory appear to be more stable cognitive domains in this
population, given that their trajectory remained constant
with age in all participants.
Contrary to our hypothesis, we were not able to identify
putative state markers for the onset of psychotic symptoms
in this population. Indeed, we did not observe significant
difference in the shape of the cognitive trajectories between
patients with and without psychotic symptoms. However,
and as hypothesized, we observed that several cognitive
domains were significantly impaired in patients with psy-
chotic symptoms, but that their developmental trajectory
was identical to the one observed in patients without psy-
chotic symptoms (referred to as intercept difference). This
suggests that low scores in these domains from childhood
are associated with an increased risk to develop psychotic
symptoms later in life and may represent early trait markers
for psychotic symptoms. In particular, this was the case for
global reasoning abilities (full-scale IQ), processing speed,
and perceptual organization. Some of these domains have
already been reported as risk factors for psychotic symp-
toms in previous 22q11DS longitudinal studies [13, 14]. It
may be the case that children with low cognitive abilities in
the context of the 22q11DS [i.e. patients scoring in the
range of intellectual disability (IQ\70) vs. patients scoring
in the borderline range of functioning or higher (IQ [70)]
have more difficulties coping with their environment and
experience it as being more unpredictable [40]. This, in
turn, could predispose to the development of anxiety,
which is a known important risk factor for schizophrenia
[4]. However, this interpretation remains speculative and
should be tested in future studies.
Conclusions
Few important limitations should be considered when
interpreting our results. First, although our longitudinal
cohort is one of the largest in Europe, the sample size is
still insufficient to perform a detailed assessment of par-
ticipants with a full-blown schizophrenia spectrum disorder
(vs. participants with psychotic symptoms). Further, there
are still limited opportunities for pooling data among
22q11DS samples, partly due to the use of different
434 Eur Child Adolesc Psychiatry (2014) 23:425–436
123
assessment tools. Several groups are currently working on
a 22q11DS Consortium to bring cohorts together and find
solutions to overcome this issue [41]. Another limitation
relates to the sole use of the SIPS criteria to assess risk for
psychosis. Further studies on 22q11DS should also include
other at-risk criteria, such as the presence of basic symp-
toms or anomalies of self-experience. Finally, the present
study included some adult participants with 22q11DS who
participated in our research following psychiatric difficul-
ties. This may have increased the prevalence of psychiatric
disorders in this subgroup. Future studies should only
include adults who were first followed longitudinally as
adolescents to avoid this ascertainment bias.
Based on the results of the present study and our clinical
experience, several final recommendations can be made.
The presence of psychotic symptoms should be explicitly
investigated and attentively monitored in 22q11DS indi-
viduals to reduce the duration of untreated psychosis and
improve outcome. Risk for schizophrenia should be eval-
uated in light of existing clinical and cognitive risk factors
(e.g. low cognitive abilities, presence of an anxiety disor-
der). Clinicians should be aware that the exacerbation of
positive psychotic symptoms occurs in most cases during
adolescence.
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